Although the efficacy of HER2-targeted therapies has been successfully demonstrated in breast cancer with HER2 overexpression/amplification, the development of HER2-targeted therapy for gastric cancer has not gone smoothly. This evidence concerns the gene ERBB2 and breast carcinoma.